Department of Acupuncture, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine.
Graduate School, Shanghai University of Traditional Chinese Medicine.
J Clin Gastroenterol. 2022 Jan 1;56(1):e77-e83. doi: 10.1097/MCG.0000000000001487.
A randomized clinical trial was undertaken to investigate the efficacy of acupoint catgut embedding (ACE) as adjunctive therapy to tauroursodeoxycholic acid (TUDCA) therapy on gallbladder emptying and clinical symptoms in patients with gallstone disease.
Between August 2018 and January 2019, 70 patients with gallstones in our hospital were enrolled in this prospective clinical trial. All the patients were randomly divided into the ACE group (ACE+TUDCA treatment for 8 wk) and the Sham group (Sham ACE+TUDCA treatment for 8 wk). In the ACE group, all the patients were nightly given ACE every 2 weeks, and in 2 groups, every patient took TUDCA 500 mg at bedtime. The parameters about gallbladder emptying were detected by ultrasound before and after the treatment, and the clinical symptom scores were recorded at the same time points.
A total of 63 patients with gallstone disease were included in our study, with 33 patients in the ACE group and 30 patients in the Sham group. In the ACE group, the empty volume (EV) and gallbladder ejection fraction (GBEF) were improved after treatment (P<0.05). Almost every symptom score (except symptom 7, P=0.15) and total score were decreased (P<0.05). In the Sham group, the symptom 1, 2, 4, 5 scores, and total score were significantly decreased (P<0.05). Moreover, the residual volume in the ACE group was significantly lower than in the Sham group (P=0.008). The EV and GBEF in the ACE group were higher than that in the Sham group (P<0.05). The score of symptom 6 in the ACE group was lower than that in the Sham group (P=0.008).
ACE therapy could more effectively improve the gallbladder emptying with a shorter treatment course. Therefore, ACE+TUDCA therapy might be a time-saving treatment for gallstones.
本研究采用随机临床试验，旨在探讨穴位埋线（ACE）作为熊去氧胆酸（TUDCA）辅助治疗在胆囊排空和胆囊疾病患者临床症状中的疗效。
2018 年 8 月至 2019 年 1 月，我院收治的 70 例胆囊结石患者纳入本前瞻性临床试验。所有患者随机分为 ACE 组（ACE+TUDCA 治疗 8 周）和 Sham 组（Sham ACE+TUDCA 治疗 8 周）。ACE 组所有患者每 2 周夜间给予 ACE 治疗，2 组患者均每晚睡前服用 TUDCA 500mg。治疗前后通过超声检测胆囊排空参数，并同时记录临床症状评分。
本研究共纳入 63 例胆囊疾病患者，ACE 组 33 例，Sham 组 30 例。ACE 组治疗后胆囊排空量（EV）和胆囊排空率（GBEF）均有改善（P<0.05）。几乎所有症状评分（除症状 7，P=0.15）和总评分均降低（P<0.05）。Sham 组症状 1、2、4、5 评分及总分明显降低（P<0.05）。此外，ACE 组残存量明显低于 Sham 组（P=0.008）。ACE 组 EV 和 GBEF 高于 Sham 组（P<0.05）。ACE 组症状 6 评分低于 Sham 组（P=0.008）。
ACE 治疗可更有效地改善胆囊排空，疗程更短。因此，ACE+TUDCA 治疗可能是一种治疗胆囊疾病的省时治疗方法。
